Adjuvant-Mediated Tumor Regression and Tumor-Specific Cytotoxic Response Are Impaired in MyD88-Deficient Mice

Cancer Research

Volumn 64, Issue 2, 2004, Pages 757-764

  Akazawa, Takashi ^a   Masuda, Hisayo ^a   Saeki, Yoshiko ^a   Matsumoto, Misako ^a,e   Takeda, Kiyoshi ^b   Tsujimura, Kunio ^c   Kuzushima, Kiyotaka ^c   Takahashi, Toshitada ^c   Azuma, Ichiro ^d   Akira, Shizuo ^b   Toyoshima, Kumao ^a   Seya, Tsukasa ^a,e  

^a OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d HAKODATE NATIONAL COLLEGE OF TECHNOLOGY   (Japan)

^e Org Pharmaceutical Safety and Res   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; INTERLEUKIN 12; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; EMULSION; MOUSE; MYCOBACTERIUM BOVIS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR IMMUNITY; TUMOR REGRESSION; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; ANTIGENS, DIFFERENTIATION; ANTIGENS, SURFACE; BCG VACCINE; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; IMMUNOTHERAPY; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; RECEPTORS, IMMUNOLOGIC; T-LYMPHOCYTES, CYTOTOXIC;

EID: 9144255378     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-1518     Document Type: Article

References (51)

1. Pardoll, D. M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol., 13: 399-415, 1995.
2. Azuma, I., and Seya, T. Development of immunoadjuvants for immunotherapy of cancer. Int. J. Immunopharmacol., 1: 1249-1259, 2001.
3. Freund, J. The mode of action of immuno-pharmacological adjuvants. Adv. Tuberc. Res., 1: 130-148, 1956.
4. Marincola, F. M., Jaffee, E. M., Hicklin, D. J., and Ferrone, S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv. Immunol., 74: 181-273, 2000.
5. Khong, H. T., and Restifo, N. P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol., 3: 999-1005, 2003.
6. Timmerman, J. M., and Levy, R. Dendritic cell vaccines for cancer immunotherapy. Annu. Rev. Med., 50: 507-529, 1999.
7. Medzhitov, R., Preston-Hurlburt, P., and Janeway, C. A. J. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature (Lond.), 388: 394-397, 1997.
8. Medzhitov, R. Toll-like receptors and innate immunity. Nat. Rev. Immunol., 1: 135-145, 2001.
9. Akira, S., Takeda, K., and Kaisho, T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat. Immunol., 2: 675-680, 2001.
10. Medzhitov, R., and Janeway, C. A. J. Innate immunity: the virtues of a nonclonal system of recognition. Cell, 91: 295-298, 1997.
11. Rescigno, M., Granucci, F., Citterio, S., Foti, M., and Ricciardi-Castagnoli, P. Coordinated events during bacteria-induced DC maturation. Immunol. Today, 20: 200-203, 1999.
12. Kaufmann, S. How can immunology contribute to the control of tuberculosis? Nat. Rev. Immunol., 1: 20-30, 2001.
13. Tsuji, S., Matsumoto, M., Takeuchi, O., Akira, S., Azuma, I., Hayashi, A., Toyoshima, K., and Seya, T. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: involvement of toll-like receptors. Infect. Immun., 68: 6883-6890, 2000.
14. Uehori, J., Matsumoto, M., Tsuji, S., Akazawa, T., Takeuchi, O., Akira, S., Kawata, T., Azuma, I., Toyoshima, K., and Seya, T. Simultaneous blocking of human Toll-like receptor 2 and 4 suppresses myeloid dendritic cell activation induced by Mycobacterium bovis bacillus Calmette-Guérin (BCG)-peptidoglycan (PGN). Infect. Immun., 71: 4238-4249, 2003.
15. Hayashi, A., Doi, O., Azuma, I., and Toyoshima, K. Immuno-friendly use of BCG-cell wall skeleton remarkably improves the survival rate of various cancer patient. Proc. Jpn. Acad., 74: 50-55, 1998.
16. Seya, T., Matsumoto, M., Tsuji, S., Begum, N. A., Azuma, I., and Toyoshima, K. Structural-functional relationship of pathogen-associated molecular patterns: lessons from BCG cell wall skeleton and mycoplasma lipoprotein M161Ag. Microbes Infect., 4: 955-961, 2002.
17. Matsumoto, M., Seya, T., Kikkawa, S., Tsuji, S., Shida, K., Nomura, M., Kurita-Taniguchi, M., Ohigashi, H., Yokouchi, H., Takami, K., Hayashi, A., Azuma, I., Masaoka, T., Kodama, K., Toyoshima, K., and Higashiyama, M. Interferon γ-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton. Int. J. Immunopharmacol., 1: 1559-1569, 2001.
18. Seya, T., Akazawa, T., Matsumoto, M., Begum, N. A., Azuma, I., and Toyoshima, K. Innate immune therapy for cancer: application of BCG-CWS and spirulina to patients with lung cancer. Anticancer Res., 23: 4369-4376, 2003.
19. Kawai, T., Adachi, O., Ogawa, T., Takeda, K., and Akira, S. Unresponsiveness of MyD88-deficient mice to endotoxin. Immunity, 11: 115-122, 1999.
20. Muzio, M., Ni, J., Feng, P., and Dixit, V. M. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science (Wash. DC). 278: 1612-1615, 1997.
21. Kaisho, T., Takeuchi, O., Kawai, T., Hoshino, K., and Akira, S. Endotoxin-induced maturation of MyD88-deficient dendritic cells. J. Immunol., 166: 5688-5694, 2001.
22. Horng, T., Barton, G. M., and Medzhitov, R. TIRAP: an adapter molecule in the Toll signaling pathway. Nat. Immunol., 2: 835-841, 2001.
23. Shapiro, A., Ratliff, T. L., Oakley, D. M., and Catalona, W. J. Reduction of bladder tumor growth in mice treated with intravesical Bacillus Calmette-Guérin and its correlation with Bacillus Calmette-Guérin viability and natural killer cell activity. Cancer Res., 43: 1611-1615, 1983.
24. Azuma, I., Ribi, E. E., Meyer, T. J., and Zbar, B. Biologically active components from mycobacterial cell walls. I. Isolation and composition of cell wall skeleton and component P3. J. Natl. Cancer Inst. (Bethesda). 52: 95-101, 1974.
25. Tanaka, H., Mori, Y., Ishii, H., and Akedo, H. Enhancement of metastatic capacity of fibroblast-tumor cell interaction in mice. Cancer Res., 48: 1456-1459, 1988.
26. Masuda, H., Saeki, Y., Nomura, M., Shida, K., Matsumoto, M., Ui, M., Lanier, L. L., and Seya, T. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-"pan" RAE-1 antibody confer tumor susceptibility to NK cells. Biochem. Biophys. Res. Commun., 290: 140-145, 2002.
27. van Elsas, A., Sutmuller, R. P., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J., Offringa, R., and Allison, J. P. Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. J. Exp. Med., 194: 481-489, 2001.
28. Inaba, K., Pack. M., Inaba, M., Sakuta, H., Isdell, F., and Steinman, R. M. High levels of a major histocompatibility complex 11-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J. Exp. Med., 186: 665-672, 1997.
29. Miconnet, I., Coste, I., Beermann, F., Haeuw, J. F., Cerottini, J. C., Bonnefoy, J. Y., Romero, P., and Renno, T. Cancer vaccine design: a novel bacterial adjuvant lot peptide-specific CTL induction. J. Immunol., 166: 4612-4619, 2001.
30. Homg, T., Barton, G. M., Flavell, R. A., and Medzhitov, R. The adaptor molecule TIRAP provides signalling specificity for Toll-like receptors. Nature (Lond.), 420: 329-333, 2002.
31. Yamamoto, M., Sato, S., Hemmi, H., Sanjo, H., Uematsu, S., Kaisho, T., Hoshino, K., Takeuchi, O., Kobayashi, M., Fujita, T., Takeda, K., and Akira, S. Essential role for TlRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature (Lond.), 420: 324-329, 2002.
32. Nishiguchi, M., Matsumoto, M., Takao, T., Hoshino, M., Shimonishi, Y., Tsuji, S., Begum, N. A., Takeuchi, O., Akira, S., Toyoshima, K., and Seya, T. Mycoplasma fermentans lipoprotein M161Ag-induced cell activation is mediated by Toll-like receptor 2: role of N-terminal hydrophobic portion in its multiple functions. J. Immunol., 166: 2610-2616, 2001.
33. Begum, N. A., Kobayashi, M., Moriwaki, Y., Matsumoto, M., Azuma, I., Toyoshima, K., and Seya, T. Identification of differentially expressed novel genes from BCG-stimulated human macrophages by cDNA subtraction and mRNA-differential display. Infect. Immun., in press, 2003.
34. Fishman, D., Irena, B., Kellman-Pressman, S., Karas, M., and Segal, S. The role of MHC class I glycoproteins in the regulation of induction of cell death in immunocytes by malignant melanoma cells. Proc. Natl. Acad. Sci. USA. 98: 1740-1744, 2001.
35. Poltorak, A., He, X., Smimova, I., Liu, M.Y., Van Huffel, C., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., Freudenberg, M., Ricciardi-Castagnoli, P., Layton, B., and Beutler, B. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science (Wash. DC), 282: 2085-2088, 1998.
36. Oshiumi, H., Sasai, M., Shida, K., Fujita, T., Matsumoto, M., and Seya, T.; Identification of the Toll-like receptor (TLR)-adapter that participates in TLR4-mediated interferon-β induction. J. Biol. Chem., 278: 49751-49762, 2003.
37. Oshiumi, H., Matsumoto, M., Funami, K., Akazawa, T., and Seya, T. TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-β induction. Nat. Immunol., 4: 161-167, 2003.
38. Seya, T., Akazawa, T., Uchori, J., Matsumoto, M., Azuma, I., and Toyoshima, K. Mechanism of tumor regression by adjuvant immunotherapy: poly(I:C) and BCG cell wall confer the unique properties on dendritic cells that lead to NK and CTL induction, Cancer Immunol. Immunother., in press, 2004.
39. Karaghiosoff, M., Steinborn, R., Kovarik, P., Kriegshauser, G., Baccarini, M., Donabauer, B., Reichart, U., Kolbe, T., Bogdan, C., Leanderson, T., Levy, D., Decker, T., and Muller, M. Central role for type 1 interferons and Tyk2 in lipopolysaccharide-induced endotoxin shock. Nat. Immunol., 4: 471-477, 2003.
40. Fujiwara, H., and Hamaoka, T. Coordination of chemokine and adhesion systems in intratumoral T cell migration responsible for the induction of tumor regression. Int. J. Immunopharmacol., 1: 613-623, 2001.
41. Honda, K., Sakaguchi, S., Nakajima, C., Watanabe, A., Yanai, H., Matsumoto, M., Ohteki, T., Kaisho, T., Takaoka, A., Akira, S., Seya, T., and Taniguchi, T. Selective contribution of IFN-α/β signaling to the maturation of dendritic cells induced by double-stranded RNA or viral infection. Proc. Natl. Acad. Sci. USA, 100: 10872-10877, 2003.
42. Matsumoto, M., Funami, K., Tanabe, M., Oshiumi, H., Shingai, M., Seto, Y., Yamamoto, A., and Seya, T. Subcellular localization of human Toll-like receptor 3 in human dendritic cells. J. Immunol., 171: 3154-3162, 2003.
43. Adachi, O., Kawai, T., Takeda, K., Matsumoto, M., Tsutsui, H., Sakagami, M., Nakanishi, K., and Akira, S. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity, 9: 143-150, 1998.
44. Sareneva, T., Julkunen, I., and Matikainen, S. IFN-α and IL-12 induce IL-18 receptor gene expression in human NK and T cells. J. Immunol., 165: 1933-1938, 2000.
45. Pardoll, D. T cells and tumors. Nature (Lond.), 411: 1010-1012, 2001.
46. Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., Zonin, F., Vaisberg, E., Churakova, T., Liu, M., Gorman, D., Wagner, J., Zurawski, S., Liu, Y., Abrams, J. S., Moore, K. W., Rennick, D., de Waal-Malefyt, R., Hannum, C., Bazan, J. F., and Kastelein, R. A. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 13: 715-725, 2000..
47. Sakaguchi, S., Sakaguchi, N., Shimizu, J., Yamazaki, S., Sakihama, T., Itoh, M., Kuniyasu, Y., Nomura, T., Toda, M., and Takahashi, T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cclls: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev., 182: 18-32, 2001.
48. Nishikawa, H., Kato, T., Miyazaki, J., Kuribayashi, K., and Shiku, H. Functional dichotomy of CD4+ T cells in tumor rejection. Jpn. J. Cancer Res., 93 (Suppl.): 127, 2002.
49. Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S. A., Gorman, D., Kastelein, R. A., and Sedgwick, J. D. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature (Lond.), 421: 744-748, 2003.
50. Diefenbach, A., Jensen, E. R., Jamieson, A. M., and Rauiet, D. H. Rael and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature (Lond.), 413: 165-171, 2001.
51. Smyth, M. J., Hayakawa, Y., Takeda, K., and Yagita, H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat. Rev. Cancer, 2: 850-861, 2002.